Oncology – Page 4

Lymph Node Isolated Tumor Cells in Ovarian Cancer: Clinically Significant or Pathological Incidentaloma?

By MedXY 03/13/2026

A large-scale cohort study of over 15,000 patients reveals that isolated tumor cells (ITCs) in regional lymph nodes do not significantly impact short-term overall survival in epithelial ovarian cancer, despite higher prevalence in low-grade serous carcinomas.

Clinical Updates news OB/GYN & Women's Health Oncology

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study

By MedXY 03/13/2026

A large-scale cohort study of premenopausal women demonstrates that adjuvant tamoxifen significantly increases the risk of endometrial cancer, hyperplasia, and polyps, with risk correlating to treatment duration.

Gastroenterology news Oncology

Rethinking the Urgency of Post-FIT Colonoscopy: Why Compliance May Take Precedence Over Speed

By MedXY 03/12/2026

A nationwide French cohort study of over 370,000 individuals reveals that delaying colonoscopy for up to 24 months after a positive FIT result does not significantly increase the risk of advanced-stage colorectal cancer, though high fecal hemoglobin levels remain a critical marker for prioritization.

Clinical Updates news Oncology

Predictive Biomarkers in PML: Preexisting Virus-Specific T Cells as Determinants of Response to Checkpoint Inhibition

By MedXY 03/12/2026

This review synthesizes recent evidence on the role of pretreatment virus-specific T cells in predicting clinical response, survival, and safety outcomes in patients with progressive multifocal leukoencephalopathy (PML) treated with immune checkpoint inhibitors.

Cardiology news Oncology

Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial

By MedXY 03/12/2026

The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and well-being, suggesting potential for individualized cardio-oncology interventions.

news OB/GYN & Women's Health Oncology

Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

By MedXY 03/12/2026

The Phase 3 SONIA trial demonstrates that delaying CDK4/6 inhibitors to the second-line setting for advanced breast cancer yields comparable overall survival to first-line use, while significantly reducing treatment-related toxicities and healthcare costs.

Gastroenterology news Oncology

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

By MedXY 03/12/2026

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness and mitochondrial health, significantly enhancing the efficacy of immune checkpoint blockade.

Clinical Updates news Oncology Pediatrics

Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma

By MedXY 03/11/2026

This review analyzes the significant long-term thyroid toxicity burden in high-risk neuroblastoma survivors, identifying key risk factors such as molecular radiotherapy, tandem myeloablative therapy, and immunotherapy.

Cardiology news Oncology

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

By MedXY 03/11/2026

This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac inflammation and mortality, offering a promising strategy for managing this life-threatening complication.

Gastroenterology news Oncology

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

By MedXY 03/11/2026

This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survival outcomes compared to those who did not.

Clinical Updates news Oncology

TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer

By MedXY 03/10/2026

This review explores the dual role of TAF2 as a basal transcription factor essential for hepatocyte survival and an oncogenic driver in hepatocellular carcinoma when overexpressed via 8q24.12 amplification.

Gastroenterology news Oncology

Universal ESD for Large Barrett’s Cancers: Shifting the Paradigm Toward Curative R0 Resection

By MedXY 03/10/2026

A multicenter study demonstrates that prioritizing endoscopic submucosal dissection (ESD) for Barrett’s cancers >15mm significantly improves R0 resection rates and survival, particularly in T1b disease, compared to traditional endoscopic mucosal resection (EMR).

Cardiology news Oncology

GnRH Antagonists May Spare the Heart: Evidence of Reduced Coronary Plaque Progression in Prostate Cancer Patients

By MedXY 03/09/2026

A randomized clinical trial indicates that the GnRH agonist leuprolide significantly accelerates coronary plaque progression compared to the antagonist relugolix in men with prostate cancer, suggesting a potential biological mechanism for differential cardiovascular risk between ADT classes.

Gastroenterology news Oncology

Global Diversity in Autoimmune Gastritis: Deciphering Regional Phenotypes and Neoplastic Risks

By MedXY 03/09/2026

An international multicentre study of 1,240 patients reveals that autoimmune gastritis presentation varies by region, with distinct risk factors—including age, intestinal metaplasia, and extreme hypergastrinemia—driving the development of gastric adenocarcinoma and neuroendocrine tumors.

Gastroenterology news Oncology

New Consensus on APC Mosaicism: Transforming the Diagnosis and Management of Unexplained Polyposis

By MedXY 03/09/2026

A landmark study in Gastroenterology reveals that APC mosaicism accounts for nearly 10% of unexplained colorectal polyposis. New guidelines recommend specific testing thresholds and surveillance strategies to prevent colorectal cancer in these high-risk patients.

news Oncology Otorhinolaryngology

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

By MedXY 03/09/2026

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signatures as a key predictor of response.

Gastroenterology news Oncology

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling

By MedXY 03/08/2026

Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vulnerability and a potential liquid biopsy biomarker.

Gastroenterology news Oncology

The Tryptophan Tug-of-War: How Faecalibacterium prausnitzii Counteracts Bacteroides fragilis in Colorectal Cancer

By MedXY 03/08/2026

A comprehensive multi-omics study reveals that Faecalibacterium prausnitzii metabolizes tryptophan into picolinic acid, which antagonizes the pro-tumorigenic effects of enterotoxigenic Bacteroides fragilis by down-regulating TCERG1 and CKAP2 genes, suggesting a potential dietary intervention for colorectal cancer.

Gastroenterology news Oncology

Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort

By MedXY 03/07/2026

This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for this biologically distinct subgroup.

Clinical Updates news Oncology

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

By MedXY 03/07/2026

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT1/STAT3 modulation.